| Bosentan for the treatment of adult pulmonary hypertension. | |
| | |
MedLine Citation:
|
PMID: 21174507 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Pulmonary hypertension is a severe progressive disease with a marked morbidity and a high mortality attributed to right heart failure. Bosentan, a dual endothelin receptor antagonist, is an effective and well-tolerated oral therapy for the management of pulmonary arterial hypertension (PAH; WHO group 1 pulmonary hypertension). Bosentan improves cardiopulmonary hemodynamics, exercise capacity, WHO functional class and quality of life, as well as delaying time to clinical worsening in patients with PAH. This article reviews the role of endothelin-1 in the pathogenesis and progression of PAH, the diagnosis of PAH and the pharmacology of bosentan, and summarizes the current available evidence for the safety and efficacy of bosentan for the treatment of PAH as a monotherapy and combination therapy, as well as its role in the management of other forms of pulmonary hypertension. |
| | |
Authors:
|
Nathan Dwyer; David Kilpatrick |
Related Documents
:
|
21642077 - Successful right coronary artery drug-eluting stent implantation in a male patient with... 21497477 - Delayed postpartum hemorrhage resulting from uterine artery pseudoaneurysm rupture. 15614847 - Prenatal sonographic delineation of the complex cardiac anatomy of thoraco-omphalopagus... 10761587 - Accessory pulsatile organs: evolutionary innovations in insects. 3596157 - Primary aortoduodenal fistula--report of an autopsy case. 22437057 - Thoracic aortic stent grafting in patients with connective tissue disorders: a word of ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Future cardiology Volume: 7 ISSN: 1744-8298 ISO Abbreviation: Future Cardiol Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-22 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101239345 Medline TA: Future Cardiol Country: England |
Other Details:
|
Languages: eng Pagination: 19-37 Citation Subset: IM |
Affiliation:
|
Cardiology Department, Royal Hobart Hospital, 48 Liverpool Street, Hobart 7000, Tasmania, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Next Document: Cardiomyocyte transverse tubule loss leads the way to heart failure.